NCT03057613View on ClinicalTrials.gov

The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

June 26, 2020

Study Completion Date

September 9, 2020

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Pembrolizumab

200mg every 3 weeks for 16 weeks given by IV infusion

RADIATION

IMRT 60-66Gy

60-66Gy for 6 weeks

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER

NCT03057613 - The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter